Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.44
EXEL's Cash to Debt is ranked lower than
89% of the 931 Companies
in the Global Biotechnology industry.

( Industry Median: 61.14 vs. EXEL: 0.44 )
Ranked among companies with meaningful Cash to Debt only.
EXEL' s Cash to Debt Range Over the Past 10 Years
Min: 0.4  Med: 1.35 Max: N/A
Current: 0.44
Equity to Asset -0.31
EXEL's Equity to Asset is ranked lower than
96% of the 703 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. EXEL: -0.31 )
Ranked among companies with meaningful Equity to Asset only.
EXEL' s Equity to Asset Range Over the Past 10 Years
Min: -3.9  Med: 0.13 Max: 0.79
Current: -0.31
-3.9
0.79
F-Score: 4
Z-Score: -7.35
M-Score: -2.66
WACC vs ROIC
14.00%
-113.59%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -326.65
EXEL's Operating margin (%) is ranked lower than
67% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -65.33 vs. EXEL: -326.65 )
Ranked among companies with meaningful Operating margin (%) only.
EXEL' s Operating margin (%) Range Over the Past 10 Years
Min: -893.86  Med: -145.27 Max: 30.91
Current: -326.65
-893.86
30.91
Net-margin (%) -456.63
EXEL's Net-margin (%) is ranked lower than
72% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -63.93 vs. EXEL: -456.63 )
Ranked among companies with meaningful Net-margin (%) only.
EXEL' s Net-margin (%) Range Over the Past 10 Years
Min: -1069.42  Med: -120.52 Max: 26.14
Current: -456.63
-1069.42
26.14
ROA (%) -54.73
EXEL's ROA (%) is ranked lower than
74% of the 935 Companies
in the Global Biotechnology industry.

( Industry Median: -26.04 vs. EXEL: -54.73 )
Ranked among companies with meaningful ROA (%) only.
EXEL' s ROA (%) Range Over the Past 10 Years
Min: -64.98  Med: -32.09 Max: 20.08
Current: -54.73
-64.98
20.08
ROC (Joel Greenblatt) (%) -6510.07
EXEL's ROC (Joel Greenblatt) (%) is ranked lower than
82% of the 899 Companies
in the Global Biotechnology industry.

( Industry Median: -363.62 vs. EXEL: -6510.07 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
EXEL' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -6260.17  Med: -487.42 Max: 766.96
Current: -6510.07
-6260.17
766.96
Revenue Growth (3Y)(%) -15.60
EXEL's Revenue Growth (3Y)(%) is ranked lower than
70% of the 478 Companies
in the Global Biotechnology industry.

( Industry Median: 4.50 vs. EXEL: -15.60 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
EXEL' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -61.3  Med: -0.40 Max: 25.7
Current: -15.6
-61.3
25.7
EBITDA Growth (3Y)(%) -7.20
EXEL's EBITDA Growth (3Y)(%) is ranked lower than
58% of the 498 Companies
in the Global Biotechnology industry.

( Industry Median: -0.80 vs. EXEL: -7.20 )
Ranked among companies with meaningful EBITDA Growth (3Y)(%) only.
EXEL' s EBITDA Growth (3Y)(%) Range Over the Past 10 Years
Min: -44.8  Med: -5.20 Max: 20.5
Current: -7.2
-44.8
20.5
EPS Growth (3Y)(%) -4.20
EXEL's EPS Growth (3Y)(%) is ranked lower than
51% of the 488 Companies
in the Global Biotechnology industry.

( Industry Median: -2.90 vs. EXEL: -4.20 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
EXEL' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -42.1  Med: -6.80 Max: 16
Current: -4.2
-42.1
16
» EXEL's 10-Y Financials

Financials (Next Earnings Date: 2016-05-04)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

EXEL Guru Trades in Q1 2015

John Burbank 78,200 sh (unchged)
Jim Simons Sold Out
» More
Q2 2015

EXEL Guru Trades in Q2 2015

Charles Brandes 25,400 sh (New)
» More
Q3 2015

EXEL Guru Trades in Q3 2015

Charles Brandes 25,400 sh (unchged)
» More
Q4 2015

EXEL Guru Trades in Q4 2015

Jim Simons 551,350 sh (New)
Charles Brandes 14,000 sh (-44.88%)
» More
» Details

Insider Trades

Latest Guru Trades with EXEL

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Top Ranked Articles about Exelixis Inc

Top-Performing Non-S&P 500 Stocks of the Year A number of non-S&P stocks beat the best performers of the index
The Standard and Poor’s 500 Index tracks 500 publicly listed companies selected by committee and having three requirements: market caps greater than or equal to $5.3 billion, annual dollar value traded to float-adjusted market cap greater than 1.0 and minimum monthly trading volume of 250,000 shares in the trailing six months of the evaluation date. Read more...

Ratios

vs
industry
vs
history
P/S 25.79
EXEL's P/S is ranked lower than
67% of the 671 Companies
in the Global Biotechnology industry.

( Industry Median: 10.84 vs. EXEL: 25.79 )
Ranked among companies with meaningful P/S only.
EXEL' s P/S Range Over the Past 10 Years
Min: 1.64  Med: 7.87 Max: 47.25
Current: 25.79
1.64
47.25
Current Ratio 3.42
EXEL's Current Ratio is ranked lower than
60% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. EXEL: 3.42 )
Ranked among companies with meaningful Current Ratio only.
EXEL' s Current Ratio Range Over the Past 10 Years
Min: 0.92  Med: 2.48 Max: 5.81
Current: 3.42
0.92
5.81
Quick Ratio 3.37
EXEL's Quick Ratio is ranked lower than
57% of the 905 Companies
in the Global Biotechnology industry.

( Industry Median: 4.54 vs. EXEL: 3.37 )
Ranked among companies with meaningful Quick Ratio only.
EXEL' s Quick Ratio Range Over the Past 10 Years
Min: 0.92  Med: 2.48 Max: 5.81
Current: 3.37
0.92
5.81
Days Inventory 230.88
EXEL's Days Inventory is ranked lower than
78% of the 441 Companies
in the Global Biotechnology industry.

( Industry Median: 121.91 vs. EXEL: 230.88 )
Ranked among companies with meaningful Days Inventory only.
EXEL' s Days Inventory Range Over the Past 10 Years
Min: 234.13  Med: 470.86 Max: 471.76
Current: 230.88
234.13
471.76
Days Sales Outstanding 50.89
EXEL's Days Sales Outstanding is ranked higher than
62% of the 602 Companies
in the Global Biotechnology industry.

( Industry Median: 65.97 vs. EXEL: 50.89 )
Ranked among companies with meaningful Days Sales Outstanding only.
EXEL' s Days Sales Outstanding Range Over the Past 10 Years
Min: 4.51  Med: 33.29 Max: 82.11
Current: 50.89
4.51
82.11
Days Payable 599.84
EXEL's Days Payable is ranked higher than
96% of the 425 Companies
in the Global Biotechnology industry.

( Industry Median: 64.47 vs. EXEL: 599.84 )
Ranked among companies with meaningful Days Payable only.
EXEL' s Days Payable Range Over the Past 10 Years
Min: 599.84  Med: 1145.74 Max: 3050.92
Current: 599.84
599.84
3050.92

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 3.29
EXEL's Price/Median PS Value is ranked lower than
89% of the 574 Companies
in the Global Biotechnology industry.

( Industry Median: 0.95 vs. EXEL: 3.29 )
Ranked among companies with meaningful Price/Median PS Value only.
EXEL' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.27  Med: 1.22 Max: 4.57
Current: 3.29
0.27
4.57
Price/Graham Number 1.28
EXEL's Price/Graham Number is ranked higher than
68% of the 293 Companies
in the Global Biotechnology industry.

( Industry Median: 2.48 vs. EXEL: 1.28 )
Ranked among companies with meaningful Price/Graham Number only.
EXEL' s Price/Graham Number Range Over the Past 10 Years
Min: 0.27  Med: 1.54 Max: 4.11
Current: 1.28
0.27
4.11
Earnings Yield (Greenblatt) (%) -9.41
EXEL's Earnings Yield (Greenblatt) (%) is ranked lower than
53% of the 897 Companies
in the Global Biotechnology industry.

( Industry Median: -7.90 vs. EXEL: -9.41 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
EXEL' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -9.41  Med: 12.50 Max: 17.5
Current: -9.41
-9.41
17.5

More Statistics

Revenue(Mil) $37
EPS $ -0.81
Beta1.66
Short Percentage of Float25.79%
52-Week Range $2.79 - 6.81
Shares Outstanding(Mil)228.19

Analyst Estimate

Dec16 Dec17
Revenue(Mil) 162 197
EPS($) -0.59 -0.43
EPS without NRI($) -0.59 -0.43

Business Description

Industry: Biotechnology » Biotechnology
Compare:SZSE:300294, SHSE:600161, NAS:NKTR, SZSE:300009, HKSE:00570, ROCO:4174 » details
Traded in other countries:EX9.Germany,
Exelixis Inc incorporated in November, 1994. It is a biotechnology company which develops small molecule therapies to treat cancer. Its two advanced assets, COMETRIQ "cabozantinib", its wholly-owned inhibitor of multiple receptor tyrosine kinases, and cobimetinib "GDC-0973/XL518", a potent, highly selective inhibitor of MEK, which it out-licensed to Genentech, Inc. a wholly-owned member of the Roche Group, or Genentech, are currently the subject of six ongoing phase 3 pivotal trials. Cabozantinib is being evaluated in a development program, including two ongoing phase 3 pivotal trials in metastatic castration-resistant prostate cancer or CRPC, an ongoing phase 3 pivotal trial in metastatic renal cell cancer or RCC, and an ongoing phase 3 pivotal trial in advanced hepatocellular cancer, or HCC. The programs that the Company runs are Cabozantinib Development Program, CRPC, COMET Pivotal Trials, Combination trials. The Company has development programs in collaboration with Genentech, GlaxoSmithKline, Bristol-Myers Squibb Company, Sanofi, Merck, Daiichi Sankyo Company Limited. It contracts third parties to manufacture raw materials, the active pharmaceutical ingredient, or API, and finished solid dose COMETRIQ products for clinical and commercial uses. The Company follows regulations set forth by FDA and comparable regulatory agencies in state and local jurisdictions and in foreign countries. Federal and state healthcare laws, including fraud and abuse and health information privacy and security laws, are applicable to the Company.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK